ROYALTY PHARMA PLC CLASS A (RPRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RPRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RPRX | Chairman and CEO; Chairman and Chief Executive Officer; Chairman of the Board and Chief Executive Officer | 62 | ["Chairman and CEO, Royalty Pharma plc","Leadership","Science / Biotech","Business Strategy","Risk Management","Corporate Responsibility","Public Company CEO","Chief Executive Officer and Chairman of the Board since inception","Former investment banker at Lazard Frères in Paris and New York","Co-founder of Pharmakon Advisors","Over 25 years of leadership experience","Demonstrated track record for delivering strong business results","Deep knowledge of investing in biopharma","Experience in the biopharmaceutical industry"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Pablo Legorreta has been our Chief Executive Officer and Chairman of the Board since inception. Previously, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a co-founder of Pharmakon Advisors, a leading provider of debt capital to the biopharmaceutical industry. Mr. Legorreta received a degree in industrial engineering from Universidad Iberoamericana in Mexico City. Mr. Legorreta brings over 25 years of leadership experience and a demonstrated track record for delivering strong business results. Mr. Legorreta has deep knowledge of investing in biopharma as he has built and managed Royalty Pharma, the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, which contributes an important perspective to our Board's discussion of opportunities and challenges in a rapidly evolving business environment. We also benefit from his extensive experience in the biopharmaceutical industry which enables him to bring a broad perspective of the issues facing our industry.